Long-term cardiology outcomes in children after early treatment for Chagas disease, an observational study

Background Parasite persistence after acute infection with Trypanosoma cruzi is an important factor in the development of Chagas disease (CD) cardiomyopathy. Few studies have investigated the clinical effectiveness of CD treatment through the evaluation of cardiological events by long term follow-up of treated children. Cardiological evaluation in children is challenging since features that would be diagnosed as abnormal in an adult’s ECG may be normal, age-related findings in a pediatric ECG trace. The objective was to evaluate cardiac involvement in patients with Chagas disease with a minimum follow-up of 6 years post-treatment. Methodology A descriptive study of a cohort of pediatric patients with CD treated with benznidazole (Bz) or nifurtimox (Nf) was conducted. Children (N = 234) with at least 6 years post CD treatment followed at the Parasitology and Chagas Service, Buenos Aires Children’s Hospital (Argentina) were enrolled. By convenience sampling, children who attended a clinical visit between August 2015 and November 2019 were also invited to participate for additional cardiovascular studies like 24-hour Holter monitoring and speckle-tracking 2D echocardiogram (STE). Benznidazole was prescribed in 171 patients and nifurtimox in 63 patients. Baseline parasitemia data was available for 168/234 patients. During the follow-up period, alterations in routine ECG were observed in 11/234 (4.7%, 95% CI [2–7.4%]) patients. In only four patients, with complete right bundle branch block (cRBBB) and left anterior fascicular block (LAFB), ECG alterations were considered probably related to CD. During follow-up, 129/130 (99%) treated patients achieved persistent negative parasitemia by qPCR. Also decrease in T.cruzi antibodies titers was observed in all patients and negative seroconversion occurred in 123/234 (52%) patients. Conclusions A low incidence of cardiological lesions related to CD was observed in patients treated early for pediatric CD. This suggests a protective effect of parasiticidal treatment on the development of cardiological lesions and highlights the importance of early treatment of infected children. Trial registration ClinicalTrials.gov NCT04090489.

[1]  J. Gascón,et al.  Worldwide Control and Management of Chagas Disease in a New Era of Globalization: a Close Look at Congenital Trypanosoma cruzi Infection , 2022, Clinical microbiology reviews.

[2]  O. Bottasso,et al.  TRYPANOCIDAL THERAPY AMONG CHILDREN INFECTED BY TRYPANOSOMA CRUZI. SEROLOGICAL AND ELECTROCARDIOGRAPHIC CHANGES OVER A MEAN TWENTY-FIVE-YEARS FOLLOW-UP PERIOD. , 2021, Acta tropica.

[3]  J. Dib,et al.  Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO) , 2021, PLoS neglected tropical diseases.

[4]  H. H. Veloso,et al.  Benznidazole decreases the risk of chronic Chagas disease progression and cardiovascular events: A long-term follow up study , 2020, EClinicalMedicine.

[5]  J. Altcheh,et al.  Adverse Events Associated with Nifurtimox Treatment for Chagas Disease in Children and Adults , 2020, Antimicrobial Agents and Chemotherapy.

[6]  L. Messenger,et al.  Chagas Disease in the United States: a Public Health Approach , 2019, Clinical Microbiology Reviews.

[7]  J. Altcheh,et al.  Longitudinal follow up of serological response in children treated for Chagas disease , 2019, PLoS neglected tropical diseases.

[8]  L. Bavia,et al.  Chagas Disease: From Discovery to a Worldwide Health Problem , 2019, Front. Public Health.

[9]  A. Ribeiro,et al.  Beneficial effects of benznidazole in Chagas disease: NIH SaMi-Trop cohort study , 2018, PLoS neglected tropical diseases.

[10]  O. Franco,et al.  Electrocardiographic abnormalities in Chagas disease in the general population: A systematic review and meta-analysis , 2018, PLoS neglected tropical diseases.

[11]  C. Rochitte,et al.  Multimodality imaging evaluation of Chagas disease: an expert consensus of Brazilian Cardiovascular Imaging Department (DIC) and the European Association of Cardiovascular Imaging (EACVI) , 2018, European heart journal cardiovascular Imaging.

[12]  E. Segura,et al.  Electrocardiographic Abnormalities and Treatment with Benznidazole among Children with Chronic Infection by Trypanosoma cruzi: A Retrospective Cohort Study. , 2016, PLoS neglected tropical diseases.

[13]  Cristiane Castro Faccini,et al.  Evaluation of Parasiticide Treatment with Benznidazol in the Electrocardiographic, Clinical, and Serological Evolution of Chagas Disease , 2016, PLoS neglected tropical diseases.

[14]  S. Yusuf,et al.  Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. , 2015, The New England journal of medicine.

[15]  J. Altcheh,et al.  Prevention of congenital Chagas through treatment of girls and women of childbearing age , 2015, Memorias do Instituto Oswaldo Cruz.

[16]  Z. Cucunubá,et al.  Follow-up of an Asymptomatic Chagas Disease Population of Children after Treatment with Nifurtimox (Lampit) in a Sylvatic Endemic Transmission Area of Colombia , 2015, PLoS neglected tropical diseases.

[17]  J. Coura,et al.  A serological, parasitological and clinical evaluation of untreated Chagas disease patients and those treated with benznidazole before and thirteen years after intervention , 2013, Memorias do Instituto Oswaldo Cruz.

[18]  B. Custer,et al.  Ten-Year Incidence of Chagas Cardiomyopathy Among Asymptomatic Trypanosoma cruzi–Seropositive Former Blood Donors , 2013, Circulation.

[19]  P. Chiodini,et al.  Chagas disease in European countries: the challenge of a surveillance system. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[20]  R. Favaloro,et al.  Accurate Real-Time PCR Strategy for Monitoring Bloodstream Parasitic Loads in Chagas Disease Patients , 2009, PLoS neglected tropical diseases.

[21]  W. Brady,et al.  Electrocardiographic manifestations: pediatric ECG. , 2008, The Journal of emergency medicine.

[22]  A. Hasslocher-Moreno,et al.  Development and validation of a risk score for predicting death in Chagas' heart disease. , 2006, The New England journal of medicine.

[23]  Rodolfo Viotti,et al.  Long-Term Cardiac Outcomes of Treating Chronic Chagas Disease with Benznidazole versus No Treatment , 2006, Annals of Internal Medicine.

[24]  S. Goodacre,et al.  Paediatric electrocardiography , 2002, BMJ : British Medical Journal.

[25]  C. Barnabé,et al.  Serologic and parasitologic demonstration of Trypanosoma cruzi infections in an urban area of central Mexico: correlation with electrocardiographic alterations. , 2001, The American journal of tropical medicine and hygiene.

[26]  A Prata,et al.  Clinical and epidemiological aspects of Chagas disease. , 2001, The Lancet. Infectious diseases.

[27]  R. Tarleton,et al.  Parasite persistence correlates with disease severity and localization in chronic Chagas' disease. , 1999, The Journal of infectious diseases.

[28]  A. Rassi,et al.  Early electrocardiographic abnormalities in Trypanosoma cruzi-seropositive children. , 1998, The American journal of tropical medicine and hygiene.

[29]  E. Segura,et al.  Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. , 1998, The American journal of tropical medicine and hygiene.

[30]  Simonne Almeida e Silva,et al.  Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection , 1996, The Lancet.

[31]  J. Maguire,et al.  Cardiac morbidity and mortality due to Chagas' disease: prospective electrocardiographic study of a Brazilian community. , 1987, Circulation.

[32]  Chagas Disease: A Clinical Approach , 2019, Birkhäuser Advances in Infectious Diseases.

[33]  C. Morillo,et al.  Recommendations for Multimodality Cardiac Imaging in Patients with Chagas Disease: A Report from the American Society of Echocardiography in Collaboration With the InterAmerican Association of Echocardiography (ECOSIAC) and the Cardiovascular Imaging Department of the Brazilian Society of Cardiology , 2018, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[34]  S. Chiu,et al.  Cardiac conduction disturbance detected in a pediatric population. , 2008, The Journal of pediatrics.

[35]  D. Fabbro,et al.  Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. , 2007, Revista da Sociedade Brasileira de Medicina Tropical.

[36]  D. Dávila,et al.  Pathogenesis of chronic chagas heart disease: parasite persistence and autoimmune responses versus cardiac remodelling and neurohormonal activation. , 2002, International journal for parasitology.

[37]  S. Goodacre,et al.  ABC of clinical electrocardiography: Paediatric electrocardiography. , 2002, BMJ.

[38]  J. C. Pinto Dias.  [Natural history of Chagas disease]. , 1995, Arquivos brasileiros de cardiologia.

[39]  E. Segura,et al.  Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. , 1994, American heart journal.